Breast Cancer (2017) 24:683–693 DOI 10.1007/s12282-017-0757-0 ORIGINAL ARTICLE Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells 1 1 1 1 • • • • Yoshikazu Koike Yusuke Ohta Wataru Saitoh Tetsumasa Yamashita 2 2 1 • • Naoki Kanomata Takuya Moriya Junichi Kurebayashi Received: 23 September 2016 / Accepted: 23 January 2017 / Published online: 31 January 2017 The Japanese Breast Cancer Society 2017 Abstract and increased apoptosis. GANT61 signiﬁcantly decreased Background Triple-negative breast cancer (TNBC) exhi- the CSC proportion in all TNBC cell lines. Paclitaxel bits biologically aggressive behavior and has a poor decreased cell growth, but not the CSC proportion. Com- prognosis. Novel molecular targeting agents are needed to bined treatments of GANT61 and paclitaxel more than control TNBC. Recent studies revealed that the non- additively enhanced anti-cell growth and/or anti-CSC canonical hedgehog (Hh) signaling pathway plays impor- activities. tant roles in the regulation of cancer stem cells (CSCs) in Conclusions The non-canonical Hh inhibitor GANT61 breast cancer. Therefore, the anti-cell growth and anti-CSC decreased not only cell growth, but also the CSC popula- effects of the non-canonical Hh inhibitor GANT61 were tion in TNBC cells. GANT61
Breast Cancer – Springer Journals
Published: Jan 31, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera